These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18812542)

  • 21. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA black box for EPO: what should nephrologists do?
    Singh AK
    Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
    [No Abstract]   [Full Text] [Related]  

  • 24. Oncologists want FDA to rethink REMS.
    Goozner M
    J Natl Cancer Inst; 2010 Dec; 102(23):1748-9, 1751. PubMed ID: 21088276
    [No Abstract]   [Full Text] [Related]  

  • 25. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
    Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
    J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reaction from renal associations. Renal Physicians Association.
    Blaser R
    Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA notifications. FDA issues public health advisory about ESAs.
    AIDS Alert; 2007 May; 22(5):57-8. PubMed ID: 17580370
    [No Abstract]   [Full Text] [Related]  

  • 29. [Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients].
    Burger S; Lehnert M; Ludwig H
    Ther Umsch; 2010 May; 67(5):271-6. PubMed ID: 20509125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 31. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 32. [The treatment of chemotherapy-induced anemia in lung cancer patients].
    Gálffy G
    Magy Onkol; 2013 Mar; 57(1):39-49. PubMed ID: 23573521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoetin for cancer patients: a boon or a danger?
    Brower V
    J Natl Cancer Inst; 2003 Dec; 95(24):1820-1. PubMed ID: 14679148
    [No Abstract]   [Full Text] [Related]  

  • 34. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
    J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New limits advised for anemia drugs.
    Mitka M
    JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
    [No Abstract]   [Full Text] [Related]  

  • 39. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
    Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
    JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
    Pedrazzoli P; Farris A; Del Prete S; Del Gaizo F; Ferrari D; Bianchessi C; Colucci G; Desogus A; Gamucci T; Pappalardo A; Fornarini G; Pozzi P; Fabi A; Labianca R; Di Costanzo F; Secondino S; Crucitta E; Apolloni F; Del Santo A; Siena S
    J Clin Oncol; 2008 Apr; 26(10):1619-25. PubMed ID: 18375891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.